IDEAL_ANSWER:
- Nivolumab was developed as a monoclonal antibody against programmed death receptor-1, an immune checkpoint inhibitor which negatively regulates T-cell proliferation and activation.

EXACT_ANSWER:
- programmed death receptor-1